Drugs / NG-350A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06459869 | Apr 2025 → Dec 2026 expected | rectal cancer | Akamis Bio | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05165433 | Apr 2022 → Aug 2025 | epithelial neoplasm, metastatic malignant neoplasm | Akamis Bio | Completed | No outcome recorded |
| Phase 1 | NCT04787991 | Aug 2021 → Nov 2024 | pancreatic adenocarcinoma | Cancer Insight, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03852511 | Feb 2019 → Feb 2022 | epithelial neoplasm, metastatic malignant neoplasm | Akamis Bio | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NG-350A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03852511 ↗ |
| Action | Activate | “full length agonist anti-CD40 antibody” NCT03852511 ↗ |
| Route | Intravenous | “NG-350A administration by intravenous (IV) infusion” NCT03852511 ↗ |
| Target | CD40 | “NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.” NCT03852511 ↗ |